TY - JOUR
T1 - Targeting Strategies for Tissue-Specific Drug Delivery
AU - Zhao, Zongmin
AU - Ukidve, Anvay
AU - Kim, Jayoung
AU - Mitragotri, Samir
N1 - Funding Information:
We sincerely acknowledge all researchers and their work in our field that we were unable to cite because of space limitations. We acknowledge support from NIH and the Wyss Institute for Biologically Inspired Engineering. S.M. is a shareholder of, consultant to, and recipient of research grants from several drug delivery, pharmaceutical, and biotechnology companies, including those active in the general area of research discussed in this article. S.M. is the inventor on several patents in the field of drug delivery and formulations that are owned by their current or former employers. The views presented here should not be considered as endorsement of any specific product or company.
Funding Information:
We sincerely acknowledge all researchers and their work in our field that we were unable to cite because of space limitations. We acknowledge support from NIH and the Wyss Institute for Biologically Inspired Engineering .
Publisher Copyright:
© 2020
PY - 2020/4/2
Y1 - 2020/4/2
N2 - Off-target effects of systemically administered drugs have been a major hurdle in designing therapies with desired efficacy and acceptable toxicity. Developing targeting strategies to enable site-specific drug delivery holds promise in reducing off-target effects, decreasing unwanted toxicities, and thereby enhancing a drug's therapeutic efficacy. Over the past three decades, a large body of literature has focused on understanding the biological barriers that hinder tissue-specific drug delivery and strategies to overcome them. These efforts have led to several targeting strategies that modulate drug delivery in both the preclinical and clinical settings, including small molecule-, nucleic acid-, peptide-, antibody-, and cell-based strategies. Here, we discuss key advances and emerging concepts for tissue-specific drug delivery approaches and their clinical translation.
AB - Off-target effects of systemically administered drugs have been a major hurdle in designing therapies with desired efficacy and acceptable toxicity. Developing targeting strategies to enable site-specific drug delivery holds promise in reducing off-target effects, decreasing unwanted toxicities, and thereby enhancing a drug's therapeutic efficacy. Over the past three decades, a large body of literature has focused on understanding the biological barriers that hinder tissue-specific drug delivery and strategies to overcome them. These efforts have led to several targeting strategies that modulate drug delivery in both the preclinical and clinical settings, including small molecule-, nucleic acid-, peptide-, antibody-, and cell-based strategies. Here, we discuss key advances and emerging concepts for tissue-specific drug delivery approaches and their clinical translation.
UR - http://www.scopus.com/inward/record.url?scp=85082424019&partnerID=8YFLogxK
U2 - 10.1016/j.cell.2020.02.001
DO - 10.1016/j.cell.2020.02.001
M3 - Review article
C2 - 32243788
AN - SCOPUS:85082424019
SN - 0092-8674
VL - 181
SP - 151
EP - 167
JO - Cell
JF - Cell
IS - 1
ER -